디지털 당뇨병 관리 시장 예측(-2030년) : 제품 유형, 최종사용자, 지역별 세계 분석

According to Stratistics MRC, the Global Digital Diabetes Management Market is accounted for $18.9 billion in 2023 and is expected to reach $52.1 billion by 2030 growing at a CAGR of 15.6% during the forecast period. Diabetes is a chronic disease that affects the body's glucose levels. This illness is mostly brought on by the pancreas' failure to make insulin or to keep the body's glucose levels stable. Devices and applications are used in diabetes care to control blood glucose levels in the body. Using these gadgets to accurately measure diabetes aids in treating patients effectively as well as recording and retaining data.

According to WHO, in 2018, the number of people suffering with diabetes has significantly risen from 108 million in 1980 to approximately 422 million in 2014. The prevalence of diabetes across the glove has increased from 4.7% to 8.5%. In 2016, around 1.6 million deaths occurred due to diabetes.

Market Dynamics:

Driver:

Advent of artificial intelligence in devices

Artificial intelligence (AI) is a fast developing field, and its applications in the diagnosis and treatment of diabetes have completely changed how we approach this long-term condition. Predictive models for the likelihood of acquiring diabetes and related complications have been developed using machine learning concepts. Clinical decision support is advantageous to both patients and healthcare providers since people are given more authority to control their diabetes on their own. This is fueling market expansion.

Restraint:

Greater acceptability

Patients still prefer the old-fashioned ways of managing their diabetes in many places. Many patients steer clear of digital platforms in favor of conventional blood glucose monitoring due to the cheap cost and lack of knowledge about connected devices and applications. The low uptake of smartphones, tablets, and laptops for diabetes treatment in various nations has also hampered the acceptability of cutting-edge technologies. Digital diabetes therapy has been made more difficult to use because to low knowledge, a shortage of qualified workers, and poor reimbursements.

Opportunity:

Increasing awareness among people

Demand for digital diabetes management devices in homecare settings is being driven by government programs to increase diabetes awareness and user-friendly insulin delivery device interfaces. The increased use of these gadgets around the globe is due to rising consumer awareness of technologically advanced items. Additionally, a significant increase in the prevalence of diabetes and several government awareness campaigns might fuel market expansion.

Threat:

Low penetration in developing economies

Comparatively fewer technologically advanced digital diabetes management platforms are used in poorer nations than in industrialized ones. This is attributed to a number of factors, including insufficient infrastructure, hazy national e-health agendas, the need to allay public concerns about data privacy and security, challenges in achieving interoperability, a shortage of qualified health informatics professionals, and a lack of regional integration strategies. This is the element impeding market expansion.

COVID-19 Impact:

The market for digital diabetes management devices was positively influenced by the epidemic. When patients with serious lung infections were brought to hospitals, controlling blood glucose levels became crucial. The patient's blood glucose levels significantly changed as a result of the disease-treating medications. Additionally, the Centers for Disease Control and Prevention underlined the elevated risk of admission to critical care that persons with diabetes and a COVID-19 diagnosis faced. Devices for managing diabetes become much more necessary as a result.

The continuous blood glucose monitoring system segment is expected to be the largest during the forecast period

The continuous blood glucose monitoring system segment is expected to be the largest during the forecast period owing to its advanced features such as compatibility with smart devices that serve as display devices. This is attributed to the factors including on-going technical advancement, an increase in product introductions, more remote monitoring technology integration into devices, and expanding public awareness. The usage of this technology will make it easier to monitor a patient's blood glucose levels in real time. It also provides a complete picture of each person's blood glucose levels.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is expected to have the highest CAGR during the forecast period. Hospitals can employ online resources or mobile applications that provide patients diabetes information, self-management tools, and support. With the use of these technologies, patients may have a better understanding of their health, track their blood sugar levels, manage their medication, and receive guidance from medical professionals.

Region with largest share:

North America is projected to hold the largest market share during the forecast period aided by the availability of advanced technologies and the recent approval of many digital blood glucose patient monitoring devices. Favorable reimbursement guidelines and governmental assistance further fuel industry expansion. Additionally, collaborations between IT firms and healthcare providers help the industry grow.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. This market is expected to develop as a result of a variety of factors, including an increase in the number of individuals with diabetes, growing healthcare costs, and an increase in the number of market competitors in the area. The expanding health awareness of diabetes and the other linked health issues, as well as the region's rising disposable income, are additional factors projected to support the expansion of this regional market.

Key players in the market

Some of the key players in Digital Diabetes Management market include: Sanofi, Medtronic, Abbott Laboratories, Bayer AG, Insulet Corporation, Dexcom, Inc., F. Hoffmann-La Roche Ltd., Johnson and Johnson, B. Braun Melsungen AG, LifeScan, Inc., Terumo corporation., Ascensia Diabetes Care Holdings AG, Novo Nordisk A/S, AGaMatrix , Care Innovaions, LLC, Tandem Diabetes, DarioHealth Corporation and Decide Clinical Software GmbH.

Key Developments:

In May 2023, Medtronic plc, a global leader in healthcare technology, announced definitive agreements for the acquisition of EOFlow Co. Ltd., manufacturer of wearable insulin patches to offer the benefits of automated insulin delivery and simplify diabetes treatment.

In April 2023, Glooko, Inc., a prominent software company, inked a Global partnership deal with Hedia, an insulin dosing algorithm company, to offer an interoperable solution that integrates remote patient monitoring, connected care, and digital therapeutic technologies to increase access to people with Type 1 and Type 2 diabetes in need of bolus insulin dosing advice.

In February 2023, Dexcom launched Dexcom G7 CGM device in the US and is planning to launch in Europe and Asia Pacific by first quarter of 2024.

Products Covered:

• Smart Insulin Pens
• Continuous Blood Glucose Monitoring System
• Smart Insulin Pumps
• Smart Glucose Meter
• Data Management Software & Platforms
• Apps
• Other Products

Types Covered:

• Wearable Devices
• Handheld Devices
• Other Types

End Users Covered:

• Diagnostic Centers
• Home settings
• Hospitals
• Academic & Research Institutes
• Specialty Diabetes Clinics
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Digital Diabetes Management Market, By Product

• 5.1 Introduction
• 5.2 Smart Insulin Pens
• 5.3 Continuous Blood Glucose Monitoring System
• 5.4 Smart Insulin Pumps
• 5.5 Smart Glucose Meter
• 5.6 Data Management Software & Platforms
• 5.7 Apps
  • 5.7.1 Weight & Diet Management Apps
  • 5.7.2 Digital Diabetes Management Apps
• 5.8 Other Products

6 Global Digital Diabetes Management Market, By Type

• 6.1 Introduction
• 6.2 Wearable Devices
• 6.3 Handheld Devices
• 6.4 Other Types

7 Global Digital Diabetes Management Market, By End User

• 7.1 Introduction
• 7.2 Diagnostic Centers
• 7.3 Home settings
• 7.4 Hospitals
• 7.5 Academic & Research Institutes
• 7.6 Specialty Diabetes Clinics
• 7.7 Other End Users

8 Global Digital Diabetes Management Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Sanofi
• 10.2 Medtronic
• 10.3 Abbott Laboratories
• 10.4 Bayer AG
• 10.5 Insulet Corporation
• 10.6 Dexcom, Inc.
• 10.7 F. Hoffmann-La Roche Ltd.
• 10.8 Johnson and Johnson
• 10.9 B. Braun Melsungen AG
• 10.10 LifeScan, Inc.
• 10.11 Terumo corporation.
• 10.12 Ascensia Diabetes Care Holdings AG
• 10.13 Novo Nordisk A/S
• 10.14 AGaMatrix
• 10.15 Care Innovaions, LLC
• 10.16 Tandem Diabetes
• 10.17 DarioHealth Corporation
• 10.18 Decide Clinical Software GmbH